Dear Colleague,

Today, China has the largest vaccine manufacturing capabilities and capacity in the world. It is also predict that China’s vaccine market demand will rise to 20% in the next few years. Recent improvements in China’s regulatory, market, and technology scenario are creating an optimistic outlook for its vaccine industry.

We invite you to attend the No.1 vaccine summit in China - VacChina 2010 - on Sept 15 and 16 in Shanghai to HEAR from 30+ internationally renowned Keynote Speakers and case studies on strategies to improve vaccine quality, safety, compliance, costs, supply and speed

Download Brochure

Key benefits of attending VacChina 2010

• Exploring the future potential of China vaccine market
• Locate the latest developments in the next generation vaccines in China
• Optimizing pre-clinical & clinical trials performance
• Managing challenges in launching the safe vaccines
• Achieving vaccine manufacturing excellence
• Revealing best practices in vaccine distribution & delivery
• Establishing industry partnerships
• Providing cost effective & large scale vaccine production strategies

Your plenary speakers @ VacChina 2010

• Weidong Yin , President & CEO , Sinovac China
• Xiaohang Ding , President of Zhejiang Tianyuan Bio-Pharmaceutical
• Bing Zeng , Vice President , Sinopharm
• Xiaohan Du , Executive Director, Vaccine Research, Simcere Pharmaceutical Group
• Pierre Trotemann , Head of Industrial Operations, Sanofi Pasteur, China
• Shou-Bai Chao , Vice President, Manufacturing, MedImmune
• Ray Yip , Director, China Program, Global Health Program, Bill & Melinda Gates Foundation
• Xinliang Shen , Director-General, National Vaccine & Serum Institute & National Engineering Research Center for Novel Vaccines (Invited)
• Shan Lu , Professor of Medicine, University of Massachusetts Medical School and Director, China-US Vaccine Research Center, Nanjing Medical University
• Kate Hermans , Head of Business Development , Pfizer China

Hear what industry insiders said about vaccine 2011 predictions and discuss this at VacChina 2010

"We are going to see a kind of cocktails of technology because you’re going to need to put together several different technologies in order to get these sophisticated new products to work." -- Kalevi Reijonen , M.D., president and CEO, FIT Biotech.

"We’re concentrated on adjuvants and I think this could easily be the year of the adjuvant in the sense that the recognition of infectious disease as a critical unmet need is on everyone’s radar screen." -- Grant Pickering , CEO, Juvaris BioTherapeutics.

"If the vaccines are safe, they’re already blockbusters." -- Rangappa Ramachandra , PhD, program director and lead scientists of immunology, Covance.

"More traditional companies will enter the vaccine environment. As you see already happening; Pfizer did." -- Benny Daniels , managing partner, Insight BioVentures.

Early bird will be extended to July 7. Please contact Daniel Chen at 86 21-3251 6046 for registration or visit the website http:///en/2010/vac/index.asp .